Bicalutamide (Casodex) in the treatment of prostate cancer.
Prostate cancer is an important healthcare issue in men worldwide. With the advent of prostate-specific antigen screening and improved diagnostic techniques, prostate cancer is now being diagnosed in younger men and at earlier disease stages. As a result, patients often live with their disease for many years after diagnosis. This shift in the patient profile has focused attention to the impact of treatment on quality of life. Medical/surgical castration has traditionally been the mainstay of hormonal therapy but is associated with side effects including loss of libido and impotence. Nonsteroidal antiandrogens such as bicalutamide (Casodex) offer an effective alternative to castration with potential quality-of-life benefits. This paper reviews the evidence concerning the use of bicalutamide at all stages of the disease.
Fradet
Yves
Y
Laval University, Cancer Research Center, CHUQ - L'Hôtel-Dieu de Québec, 11 Côte du Palais, Québec, QC G1R 2J6, Canada. fradet@attglobal.net
D000726:Androgen Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000813:Anilides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide